Sera Prognostics, Inc. (SERA) Stock Forecast Nov. 3, 2026
Analysis updated on Nov. 3, 2026 (UTC) · Alpha · vs marketSwitch to Total · Nasdaq
Sera Prognostics, Inc. (SERA) stock forecast summary
Our AI scores Sera Prognostics, Inc. every trading day against every stock it covers. Create a free account and follow it to see its rating and price target.
Sera Prognostics, Inc. is a small-cap company with a market capitalization of $78M. It ranks number 21 by market capitalization among the 26 Services-Medical Laboratories issuers in our coverage with a current forecast. Its Net Margin of -47475.7% is the lowest of the 16 peers that report one.
For SERA, the Spearman rank correlation between our 90-day forecasts and the returns that followed is 18.0%, measured on 358 forecast dates between 2022-08-16 and 2026-08-05 on this stock's own recent history. A rank correlation runs from -100% to +100%: it measures whether higher forecasts were followed by higher returns, and a value near zero or below means the model has shown little skill on this stock. On the 30-day forecasts the same correlation is 3.0%, measured on 400 forecast dates between 2022-08-16 and 2026-10-02. Across our coverage, the out-of-sample test on 4629 stocks from 2025-01-06 to 2026-08-04 produced a positive net return in 92.9% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
Expected return relative to the market over the horizon: a positive alpha means the model expects the stock to beat the market, whatever the market does. Ratings: strong buy ≥ +1.9%, buy ≥ +0.2%, sell < -0.9%, strong sell < -1.2% (top 15%, next 20%, middle 30%, next 20%, bottom 15% of the 2026-10-30 signals)
A free account shows the exact forecast, rating and rank of 3 tickers you follow, SERA included.
SERA price chart and AI forecast
How SERA ranks among 4891 stocks
90D Alpha forecasts of every company scored, cut into five relative ratings at the 15th, 35th, 65th and 85th percentiles (dashed lines).
Sera Prognostics, Inc. (SERA) fundamentals
Trailing twelve months. The industry median and the rank (1 = highest) are taken over the Services-Medical Laboratories peers listed below that report each metric.
Valuation & Market
| Metric | SERA | Rank |
|---|---|---|
| Market Cap | $78M | 21/26 |
| P/B Ratio | 1.32x | 16/21 |
| EPS | $-0.69 | – |
| Book Value/Share | $1.51 | – |
| Revenue/Share | $0.00 | – |
| FCF/Share | $-0.71 | – |
Profitability & Margins
| Metric | SERA | Rank |
|---|---|---|
| ROE | -56.0% | 12/14 |
| ROA | -38.3% | 17/18 |
| ROIC | -59.8% | 20/21 |
| Gross Margin | -152.9% | 14/15 |
| Operating Margin | -53282.9% | 21/21 |
| Net Margin | -47475.7% | 16/16 |
| EBT Margin | -46745.7% | 21/21 |
Financial Health
| Metric | SERA | Rank |
|---|---|---|
| Current Ratio | 1.98x | 16/23 |
| D/E Ratio | 0.46x | 10/21 |
| Financial Leverage | 1.46x | 10/21 |
| Interest Coverage | -5002.0x | 20/20 |
| Working Capital | $24M | 18/23 |
Cash Flow
| Metric | SERA | Rank |
|---|---|---|
| Operating Cash Flow | -$28M | 19/24 |
| Free Cash Flow | -$28M | 12/17 |
| Capital Spending | -$470K | 3/17 |
| FCF/Sales | -40211.4% | 16/16 |
| CapEx/Sales | 665.7% | 2/16 |
Operational Efficiency
| Metric | SERA | Rank |
|---|---|---|
| Asset Turnover | 0.00x | 17/18 |
| Receivables Turnover | 7.0x | 10/19 |
| Fixed Assets Turnover | 0.1x | 16/17 |
| Days Sales Outstanding | 52 days | 10/19 |
| Payables Period | 2482 days | 2/13 |
Income Statement
| Metric | SERA | Rank |
|---|---|---|
| Total Revenue | $70K | 19/19 |
| Operating Income | -$37M | 17/23 |
| Net Income | -$33M | 12/18 |
| R&D Expense | $13M | 12/18 |
| SG&A Expense | $31M | 16/18 |
| Cost of Goods Sold | $170K | 13/14 |
Dividend & Shareholder Information
| Metric | SERA | Rank |
|---|---|---|
| Shares Outstanding | 39M | – |
Balance Sheet Highlights (USD millions)
| Total Current Assets | $48M | 55.4% of assets |
| Cash & Short-term Investments | $4M | 5.1% of assets |
| Accounts Receivable | $10K | 0.0% of assets |
| Total Liabilities | $27M | 31.5% of assets |
| Short-term Debt | $23M | 26.7% of assets |
SERA quarterly financials and insider trading
Sera Prognostics, Inc. (SERA) industry peers
Companies classified under the same SEC industry code as Sera Prognostics, Inc. (Services-Medical Laboratories): 27 common-stock issuers with a forecast this week, one row per issuer, largest first. This is a classification match, not a curated list of competitors.
Reveal all forecasts · See exact % predictions for all competitors
Sign up free| Company | 90-Day AI Forecast (Alpha) | Market Cap |
|---|---|---|
| SERA Sera Prognostics, Inc. | $78M | |
| NTRA Natera, Inc. | $54.62B | |
| LH Labcorp Holdings Inc. | $28.74B | |
| DGX Quest Diagnostics Inc | $27.18B | |
| GH Guardant Health, Inc. | $23.48B | |
| CAI Caris Life Sciences, Inc. | $9.70B | |
| GRAL Grail, Inc. | $6.23B | |
| RDNT Radnet, Inc. | $5.78B | |
| BLLN Billiontoone, Inc. | $5.21B | |
| CDNA Caredx, Inc. | $4.52B | |
| VCYT Veracyte, Inc. | $3.94B | |
| CELC Celcuity Inc. | $3.38B | |
| FTRE Fortrea Holdings Inc. | $2.02B | |
| PSNL Personalis, Inc. | $1.68B | |
| FRNM Freenome, Inc. | $1.23B | |
| LMRI Lumexa Imaging Holdings, Inc. | $1.08B | |
| CSTL Castle Biosciences Inc | $1.07B | |
| FLGT Fulgent Genetics, Inc. | $533M | |
| BDSX Biodesix Inc | $222M | |
| XGN Exagen Inc. | $203M | |
| BNR Burning Rock Biotech Ltd | $117M | |
| MDXH Mdxhealth Sa | $18M | |
| AMS American Shared Hospital Services | $8M | |
| ACON Aclarion, Inc. | $5M | |
| ADVB Advanced Biomed Inc. | $3M | |
| BGLC Bionexus Gene Lab Corp | $3M | |
| RNLXY Renalytix Plc | N/A |
Where SERA sits on the market map
Sera Prognostics, Inc. (SERA) stock news
Loading...
Sera Prognostics, Inc. (SERA) stock forecast FAQ
What is the Sera Prognostics, Inc. (SERA) stock forecast?
Our AI scores Sera Prognostics, Inc. every trading day against every stock it covers. Create a free account and follow it to see its rating and price target.
How accurate are Sera Prognostics, Inc. stock predictions?
For SERA, the Spearman rank correlation between our 90-day forecasts and the returns that followed is 18.0%, measured on 358 forecast dates between 2022-08-16 and 2026-08-05 on this stock's own recent history. A rank correlation runs from -100% to +100%: it measures whether higher forecasts were followed by higher returns, and a value near zero or below means the model has shown little skill on this stock. On the 30-day forecasts the same correlation is 3.0%, measured on 400 forecast dates between 2022-08-16 and 2026-10-02. Across our coverage, the out-of-sample test on 4629 stocks from 2025-01-06 to 2026-08-04 produced a positive net return in 92.9% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
How often are Sera Prognostics, Inc. forecasts updated?
Sera Prognostics, Inc. forecasts are refreshed on trading days as the daily model run completes. The forecast on this page was produced on Nov. 3, 2026.
Which companies are Sera Prognostics, Inc.'s industry peers?
27 issuers in our coverage, SERA included, share the SEC industry code Services-Medical Laboratories. The largest are: Natera, Inc. (NTRA), Labcorp Holdings Inc. (LH), Quest Diagnostics Inc (DGX), Guardant Health, Inc. (GH), Caris Life Sciences, Inc. (CAI), Grail, Inc. (GRAL).
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.